112 related articles for article (PubMed ID: 7557897)
1. Cell kinetic analysis of non-Hodgkin's lymphomas using in vivo iododeoxyuridine incorporation and flow cytometry.
Erlanson M; Lindh J; Zackrisson B; Landberg G; Roos G
Hematol Oncol; 1995; 13(4):207-17. PubMed ID: 7557897
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle kinetics in malignant lymphoma studied with in vivo iododeoxyuridine administration, nuclear Ki-67 staining, and flow cytometry.
Brons PP; Raemaekers JM; Bogman MJ; van Erp PE; Boezeman JB; Pennings AH; Wessels HM; Haanen C
Blood; 1992 Nov; 80(9):2336-43. PubMed ID: 1421404
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
[TBL] [Abstract][Full Text] [Related]
4. In vivo determination of cell cycle kinetics of non-Hodgkin's lymphomas using iododeoxyuridine and bromodeoxyuridine.
Yanik G; Yousuf N; Miller MA; Swerdlow SH; Lampkin B; Raza A
J Histochem Cytochem; 1992 May; 40(5):723-8. PubMed ID: 1573252
[TBL] [Abstract][Full Text] [Related]
5. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis.
Begg AC; Haustermans K; Hart AA; Dische S; Saunders M; Zackrisson B; Gustaffson H; Coucke P; Paschoud N; Hoyer M; Overgaard J; Antognoni P; Richetti A; Bourhis J; Bartelink H; Horiot JC; Corvo R; Giaretti W; Awwad H; Shouman T; Jouffroy T; Maciorowski Z; Dobrowsky W; Struikmans H; Wilson GD
Radiother Oncol; 1999 Jan; 50(1):13-23. PubMed ID: 10225552
[TBL] [Abstract][Full Text] [Related]
6. Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine: intratumour sampling variations.
Begg AC; Moonen L; Hofland I; Dessing M; Bartelink H
Radiother Oncol; 1988 Apr; 11(4):337-47. PubMed ID: 3375460
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometric evaluation of proliferating cell nuclear antigen expression in human hematopoietic malignancies.
Erlanson M; Landberg G; Lindh J; Roos G
Acta Oncol; 1997; 36(1):17-22. PubMed ID: 9090958
[TBL] [Abstract][Full Text] [Related]
8. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
[TBL] [Abstract][Full Text] [Related]
9. [In vivo evaluation of potential doubling time (Tpot) of tumors by flow cytometry: practical difficulties and possible solutions].
Gorisse MC; Desoize B; Carpentier Y; Nguyen TD
Bull Cancer; 1996 Oct; 83(10):825-34. PubMed ID: 8952632
[TBL] [Abstract][Full Text] [Related]
10. Biologic progression in non-Hodgkin's lymphoma. A flow cytometric study.
Joensuu H; Klemi PJ; Jalkanen S
Cancer; 1990 Jun; 65(11):2564-71. PubMed ID: 2337874
[TBL] [Abstract][Full Text] [Related]
11. Proliferation in non-Hodgkin's lymphomas and its prognostic value related to staging parameters.
Lorand-Metze I; Pereira FG; Costa FP; Metze K
Cell Oncol; 2004; 26(1-2):63-71. PubMed ID: 15371658
[TBL] [Abstract][Full Text] [Related]
12. Growth patterns and cell kinetics of human osteosarcoma xenografts in serial passages in nude mice analyzed by in vivo labelling with iododeoxyuridine.
Broström LA; Crnalic S; Löfvenberg R; Boquist L; Stenling R
J Cancer Res Clin Oncol; 1996; 122(3):141-46. PubMed ID: 8601561
[TBL] [Abstract][Full Text] [Related]
13. Relationship between potential doubling time (Tpot), labeling index and duration of DNA synthesis in 60 esophageal and 35 breast tumors: Is it worthwhile to measure Tpot?
Haustermans K; Fowler J; Geboes K; Christiaens MR; Lerut A; van der Schueren E
Radiother Oncol; 1998 Feb; 46(2):157-67. PubMed ID: 9510043
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cell proliferation by Ki-67 staining and flow cytometry in fine needle aspirates (FNAs) of reactive lymphadenitis and non-Hodgkin's lymphomas.
Schmitt F; Tani E; Tribukait B; Skoog L
Cytopathology; 1999 Apr; 10(2):87-96. PubMed ID: 10211614
[TBL] [Abstract][Full Text] [Related]
15. Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas.
Nuutinen J; Leskinen S; Lindholm P; Söderström KO; Någren K; Huhtala S; Minn H
Eur J Nucl Med; 1998 Jul; 25(7):729-35. PubMed ID: 9662595
[TBL] [Abstract][Full Text] [Related]
16. Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results.
Tsang RW; Fyles AW; Kirkbride P; Levin W; Manchul LA; Milosevic MF; Rawlings GA; Banerjee D; Pintilie M; Wilson GD
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1319-29. PubMed ID: 7635771
[TBL] [Abstract][Full Text] [Related]
17. Cell proliferation in renal cell carcinoma. A clinical study with special reference to prognosis.
Larsson P
Scand J Urol Nephrol Suppl; 1994; 165():1-48. PubMed ID: 7871395
[TBL] [Abstract][Full Text] [Related]
18. Prognostic importance of DNA flow cytometry in non-Hodgkin's lymphomas.
Macartney JC; Camplejohn RS; Alder J; Stone MG; Powell G
J Clin Pathol; 1986 May; 39(5):542-6. PubMed ID: 3722408
[TBL] [Abstract][Full Text] [Related]
19. DNA synthesis and ploidy in non-Hodgkin's lymphomas demonstrate intrapatient variation depending on circadian stage of cell sampling.
Smaaland R; Lote K; Sothern RB; Laerum OD
Cancer Res; 1993 Jul; 53(13):3129-38. PubMed ID: 8319221
[TBL] [Abstract][Full Text] [Related]
20. Systematic heterogeneity and prognostic significance of cell proliferation in colorectal cancer.
Palmqvist R; Oberg A; Bergström C; Rutegård JN; Zackrisson B; Stenling R
Br J Cancer; 1998 Mar; 77(6):917-25. PubMed ID: 9528835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
